Navigation Links
Conatus Pharmaceuticals Initiates Confirmatory Phase 2 Clinical Trial of CTS-1027 for the Treatment of Hepatitis C Virus (HCV)
Date:2/17/2011

SAN DIEGO, Feb. 17, 2011 /PRNewswire/ -- Conatus Pharmaceuticals Inc. announced today the treatment of the first patient in a multi-center Phase 2b clinical trial evaluating CTS-1027 in combination with Peginterferon Alfa-2a (Pegasys®) and ribavirin (Copegus®) in a treatment experienced, hepatitis C (HCV) null responder patient population. Safety, tolerability, and antiviral activity of the triple combination will be assessed after up to 48 weeks of therapy.

CTS-1027 is an oral, small molecule compound that inhibits the activity of key members of a class of protease enzymes, the matrix metalloproteinases or MMPs. CTS-1027 has been shown to reduce and/or block HCV infection in in vitro preclinical models and more recently, has displayed the potential to amplify the effectiveness of existing therapies in difficult to treat HCV-infected patients. This is in addition to CTS-1027's anti-inflammatory and anti-fibrotic effects which have been well established in models of acute hepatitis and liver fibrosis.

"Our previous clinical trials indicate that CTS-1027 used in combination with existing standard-of-care HCV drugs has the potential to impact the second phase of HCV virus inhibitory kinetics in patients. This phase is associated with the gradual reduction and replacement of HCV infected cells by new uninfected liver cells. While reducing HCV virus production in infected cells is extremely important, eliminating HCV-infected cells is crucial to curing HCV," said Dr. Steven J. Mento, President and CEO of Conatus. "We believe that CTS-1027 represents a novel approach to treating HCV disease and look forward to developing this drug candidate in combination with the existing standard-of-care drugs as well as the new antiviral drugs under development."

"We have established a collaborative relationship with key opinion leaders and clinical investigators in the hepatitis community," said Ms. MiRa Huyghe, Vice President of Clinical Devel
'/>"/>

SOURCE Conatus Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Conatus Pharmaceuticals Completes $20 Million Series B Private Placement Financing
2. Conatus Pharmaceuticals Acquires Pfizers Idun Subsidiary
3. Conatus Pharmaceuticals Initiates Phase II Clinical Trial in Combination With Pegylated Interferon and Ribavirin for the Treatment of Hepatitis C Virus (HCV)
4. Conatus Pharmaceuticals to Present at the Montgomery Healthcare Conference
5. Conatus Pharmaceuticals Initiates a Second Phase 2 Clinical Trial for the Treatment of Hepatitis
6. Conatus Pharmaceuticals Reports Positive Results of CTS-1027 in Multiple Preclinical Studies of Liver Disease
7. Dr. Abraham Abuchowski of Prolong Pharmaceuticals Honored With Inaugural Tibbetts Award by the U.S. Small Business Administration
8. AVANIR Pharmaceuticals Appoints Gregory J. Flesher to Senior Vice President and Chief Business Officer
9. Savient Pharmaceuticals to Hold Fourth Quarter and Year-End 2010 Results Conference Call on Friday, February 25, 2011
10. Cumberland Pharmaceuticals to Announce 2010 Financial Results on March 8, 2011
11. Valeant Pharmaceuticals to Present at RBC Capital Markets 2011 Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014 /PRNewswire-iReach/ -- ChinaMarketResearchReports.com adds ... to its store . (Photo: ... of population, consumption upgrade and policy support, ... seen rapid development over the years, with total ... 2006 to 9.85 billion yuan in 2012. ...
(Date:1/15/2014)... Jan. 15, 2014 As health officials across ... flu virus, select Meijer pharmacies in Michigan ... and strep throat to eligible patients, enabling Meijer pharmacists ... matching prescriptions, under strict protocol set by a physician ... Grand Rapids, Mich. -based retailer is collaborating with ...
(Date:1/15/2014)... Jan. 15, 2014  Celsion Corporation (the "Company") (NASDAQ: ... has received commitments from institutional investors to purchase ... Company,s common stock in an at-the-market registered direct ... The Company entered into definitive purchase ... Company agreed to sell an aggregate of 3,603,603 ...
Breaking Medicine Technology:Orthopedic Instrument Industry in China Markets Forecast to 2015 2Orthopedic Instrument Industry in China Markets Forecast to 2015 3Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 2Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 3Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3
... (Nasdaq: AMLN ) will be presenting at the ... May 4, 2011 at 12:15 p.m. ET / 9:15 a.m. ... chief financial officer at Amylin Pharmaceuticals, will provide a corporate ... the "Investors" section of Amylin,s corporate website at www.amylin.com ...
... Idenix Pharmaceuticals, Inc. (NASDAQ: IDIX ), a ... for the treatment of human viral diseases, today reported unaudited ... 31, 2011, Idenix,s cash and cash equivalents totaled $31.4 million. ... first quarter ended March 31, 2011, Idenix reported total revenues ...
Cached Medicine Technology:Idenix Pharmaceuticals Reports First Quarter 2011 Financial Results 2Idenix Pharmaceuticals Reports First Quarter 2011 Financial Results 3Idenix Pharmaceuticals Reports First Quarter 2011 Financial Results 4Idenix Pharmaceuticals Reports First Quarter 2011 Financial Results 5
(Date:4/14/2014)... orphaned by HIV/AIDS in South Africa may provide insight ... behavior issues in other areas of the world, which ... that could lead to successful interventions. , A ... United Nations mentions that due to the HIV/AIDS pandemic, ... African, children are at an increased risk for mental ...
(Date:4/14/2014)... A new study shows that moderate to severe ... risk of stroke, cancer and death. , Results of ... to severe obstructive sleep apnea were four times more ... times more likely to have a stroke (HR = ... (HR = 3.4), and 2.5 times more likely to ...
(Date:4/14/2014)... Dallas study involving serious youth offenders, the answer to one ... seven years: "How long do you think you,ll live?", According ... offending over time., Author Dr. Alex Piquero said the study ... of them offend at very high rates and commit more ... much later in life offend much less., "In a lot ...
(Date:4/14/2014)... with symptoms increasing dramatically during some of the most important ... has found. , Depressive symptoms increased on average by 68 ... young men, who were around 25 years old when they ... their children. The results of the study were published April ... is the first to identify when young fathers are at ...
(Date:4/14/2014)... Lower weight babies and babies who aren,t breastfed ... risk of developing chronic inflammation and related health ... study. , "There were good reasons to hypothesize ... inflammation in adulthood," says Thomas McDade (Northwestern University), ... in the Child & Brain Development program. "It ...
Breaking Medicine News(10 mins):Health News:Researchers identify children with emotional behavior difficulties 2Health News:Researchers identify children with emotional behavior difficulties 3Health News:Study links severe sleep apnea to increased risk of stroke, cancer and death 2Health News:UT Dallas study: Youth who fail to envision future commit more crimes 2Health News:Young dads at high risk of depression, too 2Health News:Low birth weight, less breastfeeding create later health risks 2
... International, scientists evaluating new drug targets against tuberculosis (TB) ... could rapidly eliminate infections and potentially shorten treatment time. ... gyrase B, found in bacteria that cause TB infections. ... subunits: gyrase A and gyrase B. Although gyrase A ...
... 29 (HealthDay News) -- Nearly 40 percent of American seniors ... at least one prescription drug that is potentially unsafe or ... rate is nearly three times higher than for seniors who ... leader Dr. Yuhua Bao, an assistant professor of public health ...
... clinics between 1997 and 2008, opioid prescriptions for chronic ... study in Clinical Gastroenterology and Hepatology , the ... abdominal pain is a common symptom and a frequent ... clinicians often find it challenging to help their patients ...
... have in the decision-making, thought-processing part of your brain, the ... seem like an obvious conclusion, but a new study conducted ... the first to show this link between structure and function ... and function in people addicted to cocaine. The study appears ...
... discuss preclinical drug discovery and development at SUNY Downstate ... will take place at 12:00 noon in the Health ... Road, Brooklyn, New York 11203. Dr. Clark,s ... modified to become "Lead" compounds in the high-risk drug ...
... N.H. Runners over the age of 60 are the fastest-growing ... New Hampshire suggests that their running can remain fast as they ... Strength and Conditioning Research , found that the running economy ... of older runners was no different than that of younger runners. ...
Cached Medicine News:Health News:Medication Review May Benefit Home Health Care Patients 2Health News:Gray matter in brain's control center linked to ability to process reward 2Health News:Gray matter in brain's control center linked to ability to process reward 3Health News:Dr. Luther T. Clark to present Merck Academy Talk at SUNY Downstate 2Health News:Study: No decline in running economy for older runners 2
The Surgifresh mini has the same rugged construction as the Plume-inator. It is the ideal size for operating room, clinic and office settings. This unit includes a filter test button, hospital grade ...
... for the phakic eye, clinically validated ... of vision and visual acuity comparable ... is compatible with current cataract surgical ... the correction of myopia in whole ...
... VitalVac's advanced technology makes ... to evacuate surgical plume. ... O.R. environment is "smoke-free", ... staff safe from potentially ...
Stryker Instruments, the leader in surgical helmets, offers its 4th generation of personal protection systems for todays surgical environment the Sterishield T4 System....
Medicine Products: